Polypeptide for the Therapy of Glomerular Renal Diseases and Analysis of the Progression and Prognosis of the Dependent Syndromes

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent describes a pharmaceutical composition based on human ribonuclease 1 (or similar polypeptides) for the treatment of various renal (kidney) diseases, especially those involving damage to or loss of glomerular podocytes. It discloses that such ribonuclease can induce regeneration of these key kidney cells, supporting restoration of kidney function. The patent also covers using ribonuclease levels as a laboratory marker for monitoring the progression and prognosis of kidney diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of chronic kidney diseases such as diabetic nephropathy, glomerulonephritis, and nephrotic syndrome.
• Therapeutic intervention following acute kidney injury to support glomerular healing.
• Use in therapies to prevent or mitigate progression to end-stage renal failure requiring dialysis or transplantation.
• Monitoring kidney disease progression and therapeutic response via ribonuclease blood levels in clinical laboratories.
• Application in ex vivo filtering systems or dialysis units to remove pathogenic ribonuclease substrates.
• Development of assays for identifying kidney cell receptors related to ribonuclease activity, aiding further drug discovery.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables regeneration of glomerular podocytes, addressing a root cause of many kidney diseases.
• Potentially reduces progression to severe kidney failure, improving patient prognosis.
• Provides a specific therapy rather than just symptomatic or broadly immunosuppressive treatments for podocyte diseases.
• Offers a diagnostic tool for monitoring disease status and therapy efficacy, supporting personalized medicine approaches.
• May reduce healthcare costs by delaying or avoiding dialysis and transplantation.
• Could support development of additional targeted kidney therapies based on ribonuclease's mode of action.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A pharmaceutical composition containing human ribonuclease 1 is disclosed. The molecule according to the invention (or the analogous variants) is suitable for use as a medicament for therapy of renal diseases of various aetiologies. The drug according to the invention causes regeneration of glomerular podocytes. The molecule according to the invention can be further used by analytical determination of blood concentration as a marker of disease progression of renal syndromes and for prognosis and prevention of renal insufficiency as a valuable factor of laboratory medicine.